论文部分内容阅读
目的观察重组人生长激素(rhGH)治疗特发性矮小(ISS)的疗效。方法 2007年2月-2011年4月在本院儿科就诊并诊断为ISS的患儿62例。男38例,女24例;年龄5～12岁。每晚睡前皮下注射rhGH 0.15 IU.kg-1.d-1,观察1 a,自身比较生长速度(GV)、骨龄(BA)、体质量、身高、年龄对应的身高标准差积分(HtSDSCA)、BA对应的身高标准差积分(HtSDSBA)、BA/年龄(BA/CA)、预测成年身高(PAH)、胰岛素样生长因子-1(IGF-1)水平。结果治疗1 a后,GV由治疗前(4.03±0.69)cm.a-1提高到(8.94±1.74)cm.a-1,身高由(116.16±16.09)cm提高到(125.26±14.72)cm,HtSDSCA由-2.83±0.91提高到-2.07±0.94,HtSDSBA由0.21±1.01提高到1.14±1.25,PAH由(166.26±9.08)cm提高到(172.46±8.32)cm,治疗前后比较均有统计学差异。而BA、体质量、BA/CA、IGF-1治疗前后比较差异均无统计学意义。结论 rhGH对ISS患儿促生长作用显著,且对BA无明显影响,不良反应少。
Objective To observe the therapeutic effect of recombinant human growth hormone (rhGH) on idiopathic short stature (ISS). Methods From February 2007 to April 2011, 62 children were diagnosed as ISS in our pediatric department. 38 males and 24 females; aged 5 to 12 years old. Each group was given rhGH 0.15 IU.kg-1.d-1 subcutaneously before going to bed at night. The height standard deviation integral (HtSDSCA) corresponding to the growth rate (GV), bone age (BA), body weight, BA, BA / CA, PAH and IGF-1, respectively. Results After 1 year of treatment, the GV increased from (4.03 ± 0.69) cm.a-1 to (8.94 ± 1.74) cm.a-1 before treatment and from (116.16 ± 16.09) cm to (125.26 ± 14.72) cm HtSDSCA increased from -2.83 ± 0.91 to -2.07 ± 0.94, HtSDSBA increased from 0.21 ± 1.01 to 1.14 ± 1.25, and PAH increased from (166.26 ± 9.08) cm to (172.46 ± 8.32) cm. There was significant difference between before and after treatment. There was no significant difference between BA, body mass, BA / CA and IGF-1 before and after treatment. Conclusion rhGH has a significant effect on promoting the growth of children with ISS, and has no obvious effect on BA and little adverse reaction.